• Developing innovative drugs for aggressive drug resistant cancers

    What we do
  • Pipeline of innovative EMT inhibitors

    Pipeline

The Science of BerGenBio

BerGenBio is focused on developing innovative drugs for aggressive drug-resistant cancers. The company is a world-leader in understanding the biology of the epithelial-mesenchymal transition (EMT), a natural cellular program, which, when it occurs inappropriately, is implicated in the development of drug-resistant cancers. In EMT individual epithelial cells become more stem-cell like and resistant to hostile external environments.

Explore the science of BerGenBio